YARW
NASDAQYarrow Bioscience Inc.
Yarrow Bioscience Inc. (YARW) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 4 wire items for YARW, including 1 press release or news item, 1 analyst rating and 1 earnings update. The most recent was published Nov 12, 2026.
YARW rankings
Financial highlights
Full financials- Revenue, FY2025
- $570.0K
- Revenue growth
- +13.8%
- Net income, FY2025
- -$26.48M
- Net margin
- -4646.1%
- Free cash flow, FY2025
- -$33.12M
- Cash
- $22.93M
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks4+100%
2026-05-172026-11-08
Mix490d
- Other1(25%)
- Analyst1(25%)
- Earnings1(25%)
- SEC Filings1(25%)
Activity · 52 weeks43 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
4 items- SECYarrow Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Yarrow Bioscience, Inc. (0001566044) (Filer)
- PRYarrow Bioscience Reports Third Quarter 2026 Financial Results and Provides Business UpdateEnrollment ongoing in the Phase 2a/2b trial evaluating YB-101, a potential first-in-class anti-TSHR antibody, in patients with Graves’ disease (with or without concomitant thyroid eye disease); Phase 2a topline results expected in the second half of 2027 Completed approximately $172.5 million underwritten public offering, further strengthening the Company’s financial position to advance clinical development of YB-101 Cash and cash equivalents of $268.9 million as of September 30, 2026; expected to fund operations into 2030 Yarrow Bioscience, Inc. ("Yarrow" or the "Company") (NASDAQ:YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimm
- ANALYSTGuggenheim initiated coverage on Yarrow Bioscience with a new price targetGuggenheim initiated coverage of Yarrow Bioscience with a rating of Buy and set a new price target of $60.00
- PRYarrow Bioscience Announces Participation in November Investor EventsYarrow Bioscience, Inc. ("Yarrow" or the "Company") (NASDAQ:YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced that members of its executive team will participate in the following upcoming investor conferences: Guggenheim Securities 3rd Annual Healthcare Innovation Conference Date: Monday, November 9, 2026 Time: 1:30 p.m. ET Location: Boston, MA Format: Fireside chat and individual investor meetings Stifel Healthcare Conference Date: Tuesday, November 10, 2026 Location: New York, NY Format: Individual investor meetings Jefferies Global Healthcare Conference in London Date: November 18-19, 2026 L
YARW FAQ
11 questionsWhat does Yarrow Bioscience Inc. do?
Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company is developing YB-101, a potential first-in-class anti-thyroid stimulating hormone receptor monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease and thyroid eye disease.What is the latest news on YARW?
In the last 30 days Quantisnow tracked 4 wire items for YARW: 1 press release or news item, 1 analyst rating, 1 earnings update and 1 SEC filing. The most recent was published on November 12, 2026.What is YARW revenue?
Yarrow Bioscience Inc. (YARW) reported $570.0K of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 13.8% from the year before.Is YARW profitable?
No. Yarrow Bioscience Inc. reported a net loss of $26.48M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does YARW have?
Yarrow Bioscience Inc. reported $22.93M in cash and cash equivalents and $0 of debt on its most recent balance sheet in SEC filings.Where does YARW stock trade?
Yarrow Bioscience Inc. (YARW) is listed on NASDAQ.What sector and industry is YARW in?
Yarrow Bioscience Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Yarrow Bioscience Inc. go public?
Yarrow Bioscience Inc. (YARW) completed its IPO in 2018.What are analysts saying about YARW?
Yarrow Bioscience Inc. has had 1 recent analyst action on file. The most recent action was from Guggenheim: Buy with a $60.00 price target on 2026-11-06. Recent price targets cluster around $60.00.What companies are similar to YARW?
Notable peers in the same industry include NVO (Novo Nordisk A/S), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.). Compare YARW side-by-side with any of them on Quantisnow.How can I track YARW on Quantisnow?
Quantisnow aggregates Yarrow Bioscience Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow YARW to receive live email and push alerts on every new disclosure.